Keytruda + Lenvima demonstrated statistically significant improvement in progression-free survival , overall survival and objective response rate versus sunitinib as first-line treatment for renal cell carcinoma.- Merck Inc. + Eisai
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest